7/27/2011

The FDA approved Merz Aesthetics' Xeomin, or incobotulinumtoxinA, for temporarily reducing skin lines and wrinkles. The product is expected to be available in the U.S. next year. Dermatologist and trial investigator Joel Cohen said incobotulinumtoxinA is "more similar than it is different to other products that are on the market, particularly Botox."

Full Story:
Dermatology News

Related Summaries